APPROVE THE PLACEBO (via The Other Brother):

Human Genome's Lupus drug succeeds in trial (Toni Clarke, 7/20/09, Reuters)

Human Genome Sciences Inc said on Monday that its experimental lupus drug had succeeded in a late-stage clinical trial, shocking many who had written the product off and fueling a 195 percent jump in the company's stock. [...]

Results of the 52-week trial -- the first of two requested by U.S. regulators -- showed 57.6 percent of patients taking a high dose of Benlysta experienced an improvement in their symptoms, compared with 43.6 percent who took a placebo.